These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis.
    Author: Strandvik B, Malmborg AS, Alfredson H, Ericsson A.
    Journal: J Antimicrob Chemother; 1983 Jul; 12 Suppl A():283-7. PubMed ID: 6352633.
    Abstract:
    Ceftazidime (50 mg/kg/8 h) alone or combined with tobramycin (5 mg/kg/8 h) was given to 14 patients with cystic fibrosis. Ten courses were given with ceftazidime alone and 6 courses with a combined therapy. All patients were chronically colonized with Pseudomonas aeruginosa and were hospitalized because of lower respiratory tract infections. Using an agar-well diffusion technique, the concentration of ceftazidime was determined in serum and sputum. The mean (+/- S.E.M.) peak serum concentration of ceftazidime was 142 +/- 16 mg/l during the second to third day of treatment and 114 +/- 18 mg/l on the fifth to sixth day of treatment. In the combined therapy the corresponding values were 104 +/- 20 mg/l and 74 +/- 8 mg/l, respectively. The range of the mean half life was 1.2 to 1.4 h. The maximum concentration of ceftazidime in sputum was usually obtained 1 h after the infusion, ranging from 0.7 to 9.8 mg/l. All patients improved during treatment. Non-mucoid strains of Ps. aeruginosa were eradicated in nearly half of the courses, mucoid strains less often. No side reactions were noted.
    [Abstract] [Full Text] [Related] [New Search]